Dividends & Buybacks ·
Liminatus Pharma, Inc. received notice from Nasdaq on July 20, 2026, that it failed to regain compliance with the $1…
LIMNWLiminatus Pharma, Inc.
Liminatus Pharma, Inc. received notice from Nasdaq on July 20, 2026, that it failed to regain compliance with the $1 minimum bid price rule and is ineligible for a second 180-day extension. The company held a hearing on June 30, 2026, to request an extension, but the Nasdaq Hearings Panel has not yet issued a final decision regarding continued listing. The company must submit a written response to the Panel by July 27, 2026. Additionally, a proxy statement filed on July 13, 2026, seeks stockholder authorization for a reverse stock split at the August 3, 2026, annual meeting. Liminatus Pharma, Inc. is a pharmaceutical company.